Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2026)
Avalo Therapeutics (AVTX) posted Non-Current Deferred Tax Liability of $446000.0 for Q1 2026, up 2.76% on a QoQ basis from $434000.0 in Q4 2025, and up 60.43% year-over-year from $278000.0 in Q1 2025.
Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2026) Analysis & Trends
Avalo Therapeutics' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $446000.0 for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 60.43% year-over-year to $446000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $446000.0 (up 60.43% YoY) and the FY2025 annual result came in at $434000.0, down 69.65% from the prior year.
- Non-Current Deferred Tax Liability was $446000.0 for Q1 2026 at Avalo Therapeutics, up from $434000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.4 million in Q4 2024 and bottomed at $122000.0 in Q1 2022.
- A 5-year average of $283294.1 and a median of $162000.0 in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability jumped 822.58% — and 2025, when it tumbled 69.65%.
- Avalo Therapeutics' Non-Current Deferred Tax Liability stood at $141000.0 in 2022, then advanced by 9.93% to $155000.0 in 2023, then soared by 822.58% to $1.4 million in 2024, then tumbled by 69.65% to $434000.0 in 2025, then advanced by 2.76% to $446000.0 in 2026.
- Business Quant data shows AVTX's Non-Current Deferred Tax Liability at $446000.0 in Q1 2026, $434000.0 in Q4 2025, and $304000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Avalo Therapeutics | 1.04 Mn | 1.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 446,000.00 |
| Mar 31, 2026 | 446,000.00 |
| Dec 31, 2025 | 434,000.00 |
| Dec 31, 2025 | 434,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 278,000.00 |
| Mar 31, 2025 | 278,000.00 |
| Dec 31, 2024 | 1.43 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 154,000.00 |
| Sep 30, 2024 | 154,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Mar 31, 2024 | 162,000.00 |
| Mar 31, 2024 | 162,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Dec 31, 2023 | 155,000.00 |